37LOW

RNV

RENERVE FPO [RNV]
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and NervAlign bionic nerve and NervAlign Nerve Graft, an off-the-shelf, ready to use nerve structure for challenging nerve repairs. The company also offers deep dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; amniotic tissue product ranges, used to aid the healing of wounds; NervAlign Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; and NervAlign Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
Healthcare · ASX Small Cap
$0.0920 +3.4%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical42
Catalyst52
Sentiment50
Fundamental46
Momentum68
Risk Gate42
Get alerts when RNV's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track RNV — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Above-average volume (1.5x) on a red day — sellers in control
  • Drifting lower — down 7.1% over the last 5 days
  • Low cash runway (4 quarters) - dilution risk
  • Strong revenue growth (+60%)
  • Near 52-week low (2% of range)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (2 events)
  • Dilution velocity warning (2 raises recently)
  • CANSLIM S: Tight float (49%)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +60% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (1.77%/day)
  • Elevated dilution risk (2 recent capital raises)
  • Beneish M-Score 4.88 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about RNV
"What's driving RNV's score?" "How does RNV compare to peers?" "Key risks for RNV?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Cleansing Notice
NONE Application for quotation of securities - RNV
NONE Proposed issue of securities - RNV
LOW Half Year Investor Presentation

Recent ASX Announcements

2026-03-24 Cleansing Notice
2026-03-24 Application for quotation of securities - RNV
2026-03-23 Proposed issue of securities - RNV
2026-03-16 Half Year Investor Presentation
2026-03-09 Half Year Investor Webinar

Key Metrics

$15.9M
Market Cap
146K
Avg Volume
1.5x
Vol Ratio
$0.09 — $0.22
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-74.9%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 49%
LLeader vs LaggardlaggardRS: -2
IInstitutional SponsorshipweakInst: 1%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #110 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:RNV vs ATXRNV vs PNVRNV vs IMM
Scout Pro — Deeper Analysis for RNV
Try Pro free for 30 days
Share this analysis

Track RNV and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required